CG-0416 / CureGene Pharmaceuticals - LARVOL DELTA

Novel THR-β Agonist CG-0416 and Tirzeptide Resulting in More and Higher Quality Weight Loss in Mice (OBESITY WEEK 2026) - No abstract available

Preclinical • Fibrosis • Immunology • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants. (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: HongKong Curegene Innovation Co., Limited

New P1 trial • Genetic Disorders • Obesity

CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025 (PRNewswire) - "Data presented revealed that in diet-induced obese (DIO) mouse models, CG-0416 monotherapy demonstrated superior 'high-quality weight loss'. While achieving weight reduction comparable to semaglutide..., approximately 95% of the weight loss with CG-0416 came from fat mass reduction, with minimal muscle loss. In contrast, about one-third of semaglutide-induced weight loss was attributed to lean mass reduction."

Preclinical • Obesity